University Of Cincinnati Launches Clinical Trial To Test New Drug For Prosthetic Joint Infections

The University of Cincinnati has enrolled nan first patients successful a caller objective proceedings that will trial nan effectiveness of an investigational supplier for prosthetic associated infections (PJI).

T. Toan Le, MD, a professor successful nan Department of Orthopaedic Surgery successful nan College of Medicine, has now enrolled 2 patients successful Peptilogics' RETAIN trial.

About 5 cardinal associated replacements are performed each twelvemonth successful nan United States and Europe. Peptilogics, a surgical therapeutics company, develops treatments to forestall and cure aesculapian device-related infections (MDRI) specified arsenic prosthetic associated infections and different associated replacement infections.

"In astir 2% to 3% of these cases, nan prosthetic joints tin go infected," said Le. A biofilm forms connected nan aboveground of nan associated implant, created by germs preventing debridement, antibiotics and nan immune strategy from eradicating nan infection. The information tin hap soon aft room aliases moreover years later. 

Biofilm is nan guidelines origin of aesculapian device-related infections, and nary approved therapy has ever been designed to target it."

Jonathan Steckbeck, PhD, Peptilogics CEO

The existent modular of attraction for PJI involves a two-stage revision room to region nan infected prosthesis. A spacer is inserted and later replaced pinch a caller prosthetic joint. The process carries risks and has a nonaccomplishment complaint of up to 25%, according to Peptilogics.

The model for debridement, antibiotics and implant retention (DAIR) is constricted to astir 2 weeks aft symptoms first look aliases wrong nan first period of nan first procedure. Symptoms tin see pain, drainage, swelling and warmth astatine nan affected joint.

RETAIN is simply a randomized, double-blind, placebo-controlled, multicenter proceedings testing a peptide solution that penetrates biofilm successful patients undergoing DAIR to dainty PJI pursuing full knee replacement and forestall infection recurrence. 

"Once debridement is complete, we will usage nan peptide solution to irrigate nan infection site, leaving it successful spot connected nan prosthetic associated for astir 15 minutes toward nan extremity of surgery," said Le. In nan trial, half of patients will person nan peptide solution, and nan different half will person a saline placebo.

"If this proceedings is successful, it could make it overmuch easier for treating orthopaedic room patients to negociate infection and debar nan two-stage revision surgery," said Le. The peptide solution could besides grow nan curen model beyond conscionable 2 weeks.

The proceedings is expected to enroll 240 patients astatine up to 50 objective sites. Each diligent will beryllium monitored for persistent infection aliases recurrence for 1 twelvemonth done humor activity and session visits, telephone calls aliases virtual visits.

"It's a very well-designed objective proceedings pinch fantabulous support for each sites," said Le.